Buserelin

Buserelin is an analogue of the hormone gonadotropin-releasing hormone.

Tuyere release and composition

Buserelin nasal spray is made in vials of 17.5 ml (100 doses). 1 dose contains buserelin acetate 150 mcg (2.1 mg in one vial). Auxiliary substances are water for injection and benzalkonium chloride.

Also, Buserelin is made in the form of a solution for injection in packs of 2 5.5 ml bottles each (corresponding to 21 injections for 7-day therapy). 1 ml of solution contains 150 mcg of buserelin acetate, benzyl alcohol acts as an auxiliary component.

Indications for use

According to the instructions, Buserelin is indicated for the treatment of hormone-dependent diseases of the reproductive system, caused by partial or complete hyperestrogenism:

• Uterine fibroids;
• Endometriosis (before or after surgery);
• Infertility (during IVF program);
• Endometrial hyperplasia.

Buserelin is also indicated for the treatment of prostate cancer in cases where it is necessary to suppress the production of the hormone in the testes.

Contraindications

According to the instructions, Buserelin is forbidden to use when:

• Hypersensitivity to the active component of the drug;
• Pregnancy and breastfeeding.

In the application of Buserelin should be careful when:

• Depression;
• Diabetes;
• Hypertension.

Dosing and Administration

In the treatment of uterine fibroids, endometriosis, endometrial hyperplasia, Buserelin spray is used. The drug is introduced into the nasal passages at a dose of 900 micrograms per day, after clearing them. When the pump is fully pressed, a single dose of medication is 150 μg. The daily dose of the drug is divided into 3 doses at regular intervals (6-8 hours). Buserelin therapy is started on the first or second day of the menstrual cycle and continues to be taken for 4-6 months.

In the treatment of infertility by IVF, Buserelin spray is administered one injection intranasally (150 mcg in each nostril) 3-4 times a day at regular intervals. The daily dose of the drug should not exceed 900-1200 mg. Buserelin should be started in the follicular phase (on day 2 of the menstrual cycle) or in the middle of the luteal phase (on day 24-24). 2-3 weeks after starting the use of Buserelin with a decrease in the serum level of estradiol by no less than 50% of the baseline, as well as the thickness of the endometrium no more than 5 mm and the absence of cysts in the patient, gonadotropic hormones should be stimulated.

In the treatment of prostate cancer, subcutaneous injections of buserelin 0.5 ml three times a day every 8 hours are performed for 1 week to suppress the production of luteinizing hormone. From the second week of the patient is transferred to the spray Buserelin at a dosage of 1200 mg per day. Before breakfast, the patient takes 2 doses (in the left and right nostrils). Then take 2 doses after breakfast, before lunch, after lunch, before dinner and after dinner. The patient is prohibited to voluntarily stop the use of Buserelin or change the dosage.

When confirming hormone-dependent prostate tumors, suppression of luteinizing hormone production can be carried out throughout the patient's life.

Side effects

The use of Buserelin can cause the following side effects:

• Central nervous system: dizziness, sleep disturbance, headache, nervousness, drowsiness, fatigue, loss of concentration, memory impairment, depression, emotional lability;
• Endocrine system: vaginal dryness, lower abdominal pain, decreased libido, sensation of "flush" of blood to the skin of the face and upper chest, menstrual bleeding, bone demineralization, gynecomastia (breast enlargement in men);
• The digestive system: nausea and vomiting, abnormal stools, thirst, appetite disturbances, changes in body weight;
• Sense organs: hearing and vision impairment, tinnitus, feeling of pressure on the eyeball;
• Cardiovascular system: increased blood pressure (with hypertension), heartbeat;
• Allergies: skin rash, pruritus, urticaria, bronchospasm, skin hyperemia, anaphylactic or anaphylactoid shock, angioedema;
• Laboratory indicators: hyperglycemia, decreased glucose tolerance, increased activity of liver enzymes, changes in the lipid spectrum, leukopenia, thrombocytopenia, hyperbilirubinemia;
• Other side effects of buserelin: swelling in the ankles and feet, pulmonary thromboembolism, nasal bleeding (extremely rare), pain in the joints and back, increased or weakened hair growth on the body and head;
• Local reactions: irritation, dryness of the nasal mucosa, pain in the nose.

special instructions

Depressed patients should be under the supervision of a physician during Buserelin.

In the initial stage of treatment is not excluded the development of ovarian cysts.

A repeated course of treatment with Buserelin is possible only after a balance of risks and benefits for the patient. There is a potential risk of osteoporosis.

If the patient uses contact lenses, signs of eye irritation are not excluded.

When using the drug in the form of a spray, irritation of the nasal mucosa and nosebleeds are possible. With rhinitis, buserelin can be used, however, having previously cleaned the nasal passages.

The use of the drug in combination with surgery for endometriosis reduces the severity of pathological foci and their blood supply, eliminates inflammatory processes and reduces the time of surgery. Postoperative therapy with buserelin reduces the risk of recurrence and reduces the formation of adhesions.

During treatment with Buserelin, it is necessary to carefully manage potentially dangerous mechanisms that require increased concentration of attention.

Analogs

Structural analogue of Buserelin is the drug Suprefakt.

Terms and conditions of storage

According to the instructions, Buserelin belongs to the drugs on list B, which should be stored in a dry, dark, cool and protected from children place. Shelf life of the drug - 3 years.